Current status of multiple markers in precision immunotherapy for colorectal cancer
Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related mortality. While early-stage CRC patients generally exhibit favorable overall survival (OS) rates, the prognosis for metastatic CRC (mCRC) remains poor, with a survival rate < 15%.
Authors
- Chao Liu (ORCID: https://orcid.org/0009-0003-2203-1502)
- Yanqiao Zhang (ORCID: https://orcid.org/0000-0002-6206-8364)
- Hong Wang (ORCID: https://orcid.org/0000-0002-4879-4482)
- Ya Lan
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Heilongjiang University (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2025-03-26
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2025.0030
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00